M. Di Maio - Clinical Trials Unit | 人才画像

基本信息

浏览量：158

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 93 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Cancer care in transgender and gender-diverse persons: results from two national surveys among providers and health service users by the Italian Association of Medical Oncology

A G Leone, R Miceli, D Trapani, M Massagrande, F Morano, S Marsoni,N La Verde,R Berardi, R Casolino,M Lambertini, D Dalu,M Di Maio,

ESMO openno. 3 (2023): 101578

引用0浏览0WOS引用

COVID-19 Long-Lasting Effect on Lung Cancer Diagnoses in Italy: Update of the Real-World Multicenter COVID-DELAY Study

G. Mentrasti, V. Cognigni, T. Galassi, D. Signorelli, E. G. Pizzutilo, F. Martinelli,G. Lo Russo, R. Leporati, P. Ambrosini, R. Giusti, S. D'Amuri, D. Rocco,

JOURNAL OF THORACIC ONCOLOGYno. 11 (2023): S742-S743

引用0浏览0引用

2088P Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey among Italian oncologists

A.A. Valsecchi, V. Fusco,M. Di Maio,D. Santini, M. Tucci,U.F.F. De Giorgi, R. Dionisio, F. Vignani, S. Cinieri

Annals of Oncology (2023): S1097-S1098

引用0浏览0引用

Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM)

P Pedrazzoli,A Lasagna,I Cassaniti, A Piralla,A Squeri, R Bruno, P Sacchi,F Baldanti,M Di Maio,G D Beretta, S Cinieri,N Silvestris

ESMO openno. 3 (2023): 101215-101215

引用3浏览0WOS引用

933P Real-world patterns of immunotherapy utilization and outcomes in recurrent/metastatic head and neck cancer (R/M HNC) patients across European countries: A multicenter retrospective federated analysis

G. Plavc, R.S. Calisto, C. Paratore,M.J. Lostes Bardaji, E. Hallan Naderi, T. Rutkowski, A. Kovac, A. Cortez, G. Pretelli, I. Braña,C. Vieira, M.J. Bento,

Annals of Oncology (2023): S587-S587

引用0浏览0引用

1760P Systematic review of quality of life (QoL) inclusion among endpoints, reporting and impact of QoL results in phase III non-inferiority trials of systemic treatments in oncology